Pharma major Bharat Biotech has received approval from India’s drug regulator to conduct mid-to late-stage trials of their nasal Covid-19 vaccine candidate, the Union ministry of science said on Friday.

“This is the first of its kind Covid-19 jab to undergo human clinical trials in India,” the ministry said. 

“BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis, USA,” it added. 

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint.
Download
our App Now!!



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here